Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock

Eli Lilly & Co. LLY may be down over 8% in the past month and nearly 5% over the past five days, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down.Zepbound's Momentum Keeps Eli Lilly In The LeadWith Zepbound continuing to dominate the GLP-1 obesity category and new catalysts on the horizon, JPMorgan sees Eli Lilly as still one of the top picks in the sector.Prescriptions for both Zepbound and Mounjaro are running ahead of expectations in the second quarter, positioning Eli Lil ...